<p>This commentary explores the evolving landscape of United States healthcare policy and its global implications, specifically in cardiovascular and thrombosis associated conditions. Recent legislative and executive actions have introduced sweeping reforms to federal programs such as Medicaid, Medicare, and drug pricing (Medicare Drug Price Negotiation, Medicaid Drug Rebate, Federal Supply Schedule) threatening access and affordability for millions of Americans-many already vulnerable and at risk for life threatening and life altering events. These changes reverberate internationally, influencing research collaborations, supply chains, accessibility, and the cost of care. This commentary advocates for evidence-based policy, multi-level collaboration, increased international education directives, and an unwavering commitment to broad-based healthcare access worldwide.</p>